Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up study

Hashimoto, Etsuko; Shimada, Masahiko; Noguchi, Sanshirou; Taniai, Makiko; Tokushige, Katsutoshi; Hayashi, Naoaki; Takasaki, Ken; Fuchinoue, Syouhei; Ludwig, Jürgen

doi:10.1053/jlts.2001.25357

Cited by 66 publications

(47 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically, it can be asymptomatic; total serum bilirubin level and hepatic biochemistry are normal, although serum alkaline phosphatase may be slightly increased. 128,129 Risk factors remain unclear but probably include histocompatibility leukocyte antigen or sex mismatching between donor and recipient 130 and immunosuppression. 131 Dmitrewski et al 131 reported that histologic features characteristic of PBC were found more commonly and earlier after transplantation in patients receiving FK506 than in those given cyclosporine.…”

Section: Recurrent Cholestatic Diseasementioning

confidence: 99%

Intrahepatic cholestasis after liver transplantation

Ben‐Ari

Pappo

Mor

2003

Liver Transplantation

View full text Add to dashboard Cite

Cholestasis is a common sequela of liver transplantation. Although the majority of cases remain subclinical, severe cholestasis may be associated with irreversible liver damage, requiring retransplantation. Therefore, it is essential that clinicians be able to identify and treat the syndromes associated with cholestasis. In this review, we consider causes of intrahepatic cholestasis. These may be catego-

show abstract

Section: Recurrent Cholestatic Diseasementioning

confidence: 99%

Intrahepatic cholestasis after liver transplantation

Ben‐Ari

Pappo

Mor

2003

Liver Transplantation

View full text Add to dashboard Cite

show abstract

“…The number of patients in Hashimoto's study [24] is too small to draw a definitive conclusion. The high rate of recurrence (33% in 2 years) is in sharp contrast with that in an earlier DDLT series.…”

Section: Pbcmentioning

confidence: 96%

“…Hashimoto and colleagues presented the first series of recurrent PBC after LDLT [24] . All patients remained positive for AMA as in DDLT.…”

Section: Pbcmentioning

confidence: 99%

Recurrence of cholestatic liver disease after living donor liver transplantation

Tamura¹,

Sugawara²,

Kaneko³

et al. 2008

WJG

View full text Add to dashboard Cite

End-stage liver disease, due to cholestatic liver diseases with an autoimmune background such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), is considered a good indication for liver transplantation. Excellent overall patient and graft outcomes, based mostly on the experience from deceased donor liver transplantation (DDLT), have been reported. Due to the limited number of organ donations from deceased donors in most Asian countries, living donor liver transplantation (LDLT) is the mainstream treatment for end-stage liver disease, including that resulting from PBC and PSC. Although the initial experiences with LDLT for PBC and PSC seem satisfactory or comparable to that with DDLT, some aspects, including the timing of transplantation, the risk of recurrent disease, and its long-term clinical implications, require further evaluation. Whether or not the long-term outcomes of LDLT from a biologically related donor are equivalent to that of DDLT requires further observations. The clinical course following LDLT may be affected by the genetic background shared between the recipient and the living related donor.

show abstract

“…[52][53][54][55] Recently, a report has noted the recurrence of primary biliary cirrhosis after living donor liver transplantation. 56 However, because there is considerable histologic overlap between chronic rejection and recurrent PBC, the diagnosis can be challenging. However, patients with chronic rejection usually are distinguishable by having a history of multiple acute rejection episodes, which often differentiates patients with chronic rejection from those with recurrent PBC.…”

Section: S65mentioning

confidence: 99%

Late hepatic allograft dysfunction

Wiesner

2001

Liver Transplantation

View full text Add to dashboard Cite

Key Points1. Lifelong monitoring of graft function, immunosuppressive levels, and screening for drug toxicity is required in all liver recipients.2. Late hepatic allograft dysfunction is common and is caused by a variety of etiologies including rejection, infection, biliary/vascular abnormalities, recurrence of disease, and drug hepatotoxicity.3. In all patients with late hepatic allograft dysfunction, liver biopsy should be performed to assess for the presence of rejection, and to thus avoid excessive use of bolus corticosteroid therapy and guide appropriate immunosuppressive management.4. Recurrence of disease is the most common cause of late hepatic allograft dysfunction.5. Hepatitis C universally reinfects the hepatic allograft, and is associated with decreased patient and graft survival and leads to the recurrence of cirrhosis in 28% of patients within 5 years of transplantation.

show abstract

Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up study

Cited by 66 publications

References 31 publications

Intrahepatic cholestasis after liver transplantation

Intrahepatic cholestasis after liver transplantation

Recurrence of cholestatic liver disease after living donor liver transplantation

Late hepatic allograft dysfunction

Contact Info

Product

Resources

About